Chris McNally
Chris McNally, PhD, has a strong foundation in Biomedical Science, earning his BSc from Ulster University and completing a PhD scholarship in collaboration with Randox Laboratories and Ulster University. Chris has published extensively in prostate cancer research, focusing on biomarker discovery, cancer risk stratification, and molecular mechanisms such as hypoxia-induced regulation. He currently serves as a Business Development Manager at Assay Genie.
Connect with Chris or explore his work:
Blogs by Chris:
What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is the mechanism of action for Varlilumab?Varlilumab enhances immune responses by activating CD27 signaling, promoting T-cell [...]
Ifabotuzumab is a monoclonal antibody targeting the EGFRvIII mutation, a tumor-specific variant of the epidermal growth factor receptor (EGFR). This mutation is associated with aggressive tumor growth, especially in glioblastoma multiforme (GBM) and other cancers. The biosimilar HDBS0019 replicates the efficacy and safety [...]
Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key receptor in the immune system. By blocking CD40-CD40L interactions, Iscalimab inhibits immune activation, making it a promising therapy for autoimmune diseases, transplant rejection, and other immune-mediated conditions. The biosimilar HDBS0020 replicates Iscalimab’s efficacy [...]
Publications by Chris:
